Updates are available Correction dated 2025-03-12
Click to view Correction: https://doi.org/10.1186/s12969-025-01077-4
-
Authors
Nozawa, Tomo
Iwata, Naomi
Igarashi, Toru
Kobayashi, Ichiro
Ota, Shoji
Yamada, Takako
Bando, Etsuya
Habiro, Katsuyoshi
Takei, Syuji
-
Funding
Funding for this research was provided by:
Bristol-Myers Squibb
- License Information
-
More Information
Article History
Received: 11 December 2024
Accepted: 31 January 2025
First Online: 19 February 2025
Change Date: 12 March 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12969-025-01077-4
Declarations
:
: This PMS study was conducted in accordance with Good Postmarketing Surveillance Practices and the ethical principles of the Declaration of Helsinki. Informed consent was obtained from all participants in the study. The ethics review board of each participating institution approved this study.
: Not applicable.
: N. I. received honoraria for lectures from AbbeVie GK, Mitsubishi Tanabe Pharma Corporation, and GlaxoSmithKline K.K. and for serving as a moderator from AYUMI Pharmaceutical Corporation. S. T. received research grants from Chugai Pharmaceutical Co. Ltd. and honoraria for speakers' bureaus from AbbVie GK, AstraZeneca plc, Astellas Pharma Inc., AYUMI Pharmaceutical Corporation, Chugai Pharmaceutical Co. Ltd., Eisai Co., Ltd., GlaxoSmithKline K.K., Mitsubishi Tanabe Pharma Corporation, Novartis Pharmaceuticals, and ONO PHARMACEUTICAL CO., LTD. S.O., T. Y., E.B., and K.H. are employees of Bristol Myers Squibb and own stock in Bristol Myers Squibb. All other authors declare no conflicts of interest associated with this manuscript.
